相關搜尋:
According to the panel, vaccine manufacturers should design updated vaccines to target the JN.1 variant of SARS-CoV-2. Ideally, these ...
Forbes
2 日前
Reuters
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say
Should You Pick Moderna Stock At $150 After 25% Gains In A Month?
9 小時前
FDA Panel Recommends New COVID Vaccines For JN.1 Lineage By Fall
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says
4 日前
CNBC
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
Bloomberg
Moderna’s RSV Shot Wins FDA Approval for Use in Older Adults
7 日前
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes Daily: Look Out New York, Texas Could Get Its Own Stock Exchange
1 日前
Noubar Afeyat MIT Commencement: Imagination – And Action!
查看全部